HomeCompareSPCNF vs PFE

SPCNF vs PFE: Dividend Comparison 2026

SPCNF yields 4761.90% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPCNF wins by $38747342250320.00M in total portfolio value
10 years
SPCNF
SPCNF
● Live price
4761.90%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38747342250320.05M
Annual income
$37,210,182,950,502,500,000.00
Full SPCNF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SPCNF vs PFE

📍 SPCNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPCNFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPCNF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPCNF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPCNF
Annual income on $10K today (after 15% tax)
$404,761.90/yr
After 10yr DRIP, annual income (after tax)
$31,628,655,507,927,120,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SPCNF beats the other by $31,628,655,507,927,100,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPCNF + PFE for your $10,000?

SPCNF: 50%PFE: 50%
100% PFE50/50100% SPCNF
Portfolio after 10yr
$19373671125160.05M
Annual income
$18,605,091,475,251,260,000.00/yr
Blended yield
96.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SPCNF
No analyst data
Altman Z
19.7
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPCNF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPCNFPFE
Forward yield4761.90%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$38747342250320.05M$49.6K
Annual income after 10y$37,210,182,950,502,500,000.00$26,258.71
Total dividends collected$38643169569237.57M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPCNF vs PFE ($10,000, DRIP)

YearSPCNF PortfolioSPCNF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$486,890$476,190.48$9,153$693.39+$477.7KSPCNF
2$22,189,441$21,668,468.01$8,593$849.25+$22.18MSPCNF
3$946,653,034$922,910,331.94$8,336$1,066.78+$946.64MSPCNF
4$37,810,578,817$36,797,660,071.11$8,437$1,384.80+$37810.57MSPCNF
5$1,414,053,011,920$1,373,595,692,585.52$9,013$1,875.40+$1414053.00MSPCNF
6$49,522,572,653,995$48,009,535,931,241.25$10,306$2,680.72+$49522572.64MSPCNF
7$1,624,369,209,472,066$1,571,380,056,732,291.00$12,820$4,101.38+$1624369209.46MSPCNF
8$49,908,337,240,992,536$48,170,262,186,857,420.00$17,673$6,826.70+$49908337240.97MSPCNF
9$1,436,597,476,465,005,300$1,383,195,555,617,143,300.00$27,543$12,591.86+$1436597476464.98MSPCNF
10$38,747,342,250,320,050,000$37,210,182,950,502,500,000.00$49,560$26,258.71+$38747342250320.00MSPCNF

SPCNF vs PFE: Complete Analysis 2026

SPCNFStock

SPC Nickel Corp. engages in the acquisition, exploration and development of mineral properties in Canada. It primarily explores for nickel, copper, and platinum group metals. The company holds interest in the Aer-Kidd property located on the Worthington Offset Dyke in the Sudbury mining district; and the Lockerby East and West Graham exploration properties located in the Sudbury district. It also holds an option agreement to acquire a 100% interest in the Janes property situated in northeast Sudbury. The company was formerly known as Sudbury Platinum Corporation and changed its name to SPC Nickel Corp. in December 2020. SPC Nickel Corp. was incorporated in 2013 and is based in Toronto, Canada.

Full SPCNF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SPCNF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPCNF vs SCHDSPCNF vs JEPISPCNF vs OSPCNF vs KOSPCNF vs MAINSPCNF vs JNJSPCNF vs MRKSPCNF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.